Good news!

On December 22, it was reported that Shenzhen Weijiejun Biotechnology Co.
, Ltd.
(hereinafter referred to as "Unknownjun"), an AI pharmaceutical company focused on intestinal microecological treatment, announced the completion of a new round of financing.
So far, a series of B series with a total of nearly 100 million US dollars The financing has been completed
.
The funds raised are expected to be used for the development of drug clinical trials, IND application projects in the United States and China, and the research and development of candidate drug pipelines; at the same time, it will be used to actively promote the introduction of commercial authorization and cooperation with major pharmaceutical companies, accelerate the process of internationalization, and build an American innovation center , To accelerate the company's technology platform upgrade and iteration, and release the energy of the "independent research and development + platform empowerment" pharmaceutical research system
.
It is reported that this financing of the unknown has attracted many domestic and foreign investment institutions such as Legend Capital, Gaorong Capital, Yunjiu Capital, Wuyuan Capital, Chunhua Capital, and Shanxing Capital.
It can be seen that investors have affirmed the unknown.
And optimistic about the field of intestinal microecological AI pharmaceuticals
.
Micro-ecology is closely related to people's health
.
According to scientific and clinical research, intestinal microecological disorders are directly related to at least 50 kinds of diseases, including diabetes, obesity, tumors, and autism
.
Microecological drugs refer to pharmaceutical preparations made from normal microorganisms or substances that regulate the normal growth of microorganisms, covering intestinal microbes, oral microbes, reproductive tract microbes and skin microbes.
Intestinal microbes are the main focus area.
Pharmaceutical companies account for more than 90%
.
It is estimated that the permeable market size of microecological drugs can reach 100 billion U.
S.
dollars
.
In China, the microbial industry is also a strategic direction that the country attaches great importance to
.
However, from the perspective of the development of the entire industry, compared with traditional pharmaceuticals, there has not been any microecological drug officially approved for marketing globally.
The United States and Europe are relatively leading, while China and even the entire Asia, microecological pharmaceuticals are still In its infancy
.
It is understood that there are more than 1,000 types of intestinal microbes in the human body, and the number of strains is even greater.
How to find strains that have a therapeutic effect on diseases is very time-consuming, energy-intensive and cost-intensive.
Under traditional methods, pharmaceutical companies mainly use large-scale screening, cultivation, and It is time-consuming and labor-intensive to test for druggability to find curable strains
.
In the pharmaceutical process, AI can help to quickly find effective key bacteria, improve the efficiency of microbial drug development and pharmaceutical efficiency, shorten development time, reduce costs, and reduce risks
.
Unknown Jun is the first AI micro-ecological pharmaceutical company in China.
The company's self-developed drugs have entered the stage of registered clinical trials.
In June 2021, unknown Jun's intestinal bacteria transplantation (FMT) drug was approved by the U.
S.
FDA.
The approval document officially entered the clinical trial stage
.
In China, this project has also recently submitted a Pre-IND application to the Center for Drug Evaluation (CDE) of the State Drug Administration
.
Up to now, Mingjun has five self-developed First-in-class microecological drug pipelines, and many clinical drugs have shown significant efficacy
.
At the same time, the company is also actively expanding the drug pipeline through commercial authorization introduction and cooperative development.
For example, in May 2021, the company and 3SBio reached a joint development agreement for the treatment of kidney disease in the field of whole bacteria capsules
.
The industry pointed out that cooperation between intestinal microecological pharmaceutical companies and large international pharmaceutical companies has become a major trend
.
Recently, some related companies and drugs have appeared in the global micro-ecological pharmaceutical industry, which means that the global micro-ecological medicine has entered the mature stage of transformation
.
Unknown Jun said that he will seize this development opportunity and start a new strategy of "AI×BT"-continue to optimize the company's business structure, integrate AI and BT technologies and talents in depth, and develop self-developed drugs and external empowerment The two directions go hand in hand to further improve the conversion efficiency of microecological drugs and build a technology platform with core competitiveness; deploy multiple self-research and license-in drug asset pipelines to create a microbial drug asset incubation platform
.